hsa-mir-634: Hsa-mir-634 is a microRNA that is up-regulated in atrial fibrillation and coronary artery disease [13,42]. It has also been found to be involved in heart remodeling in patients with idiopathic dilated cardiomyopathy [43]. Another microRNA, hsa-mir-520h, is expressed in human heart disease [44]. Hsa-mir-450b-3p is regulated by ischemia [45]. TLR2 has been identified as a critical regulator in acute myocardial infarction (AMI) and a potential biomarker for AMI detection [46–48]. Blocking the NFKBIA-mediated NF-κB signaling pathway has shown to protect against myocardial infarction (MI) [49]. High levels of ADM are related to impaired left ventricular function and death in patients with AMI [50–52] [PMC8863347] [13] [42] [43] [44] [45] [46–52]. In addition, hsa-mir-634 has been found to be common between the targeted miRNAs of circCOL1A1 and the differentially expressed miRNAs [PMC8960148]. It is also common between the targeted miRNAs of circCEACAM5 and the differentially expressed miRNAs [PMC8960148] [PMC8960148]. Hsa-mir-634 has been found to be downregulated in osteoarthritis [PMC4366666], while it is upregulated in non-small-cell lung cancer pathway and pancreatic adenocarcinoma tumor groups compared to normal groups [PMC3091682] [PMC9669652] [PMC4366666] [PMC3091682] [PMC9669652]. In summary, hsa-mir-634 plays a role in various cardiovascular diseases such as atrial fibrillation, coronary artery disease, dilated cardiomyopathy, ischemia, acute myocardial infarction (AMI), and myocardial infarction (MI) [13,42,43,45,46–52]. It also shows differential expression patterns in osteoarthritis [PMC4366666], non-small-cell lung cancer pathway, and pancreatic adenocarcinoma [PMC3091682] [PMC9669652].